The National Institute of Allergy and Infectious Diseases (NIAID) is offering this grant to support Small Business Innovation Research (SBIR) Phase II clinical trials. This grant is specifically designed for investigator-initiated, hypothesis-driven, and milestone-driven clinical trials that align with NIAID’s crucial research mission. While standard clinical trials are welcome, the program strongly encourages high-risk clinical studies. ‘High-risk’ in this context defines studies involving non-routine interventions, the administration of unlicensed products, or the use of licensed products for unapproved indications. Mechanistic studies are also a key focus and are highly encouraged under this valuable funding opportunity.
Opportunity ID: 352061
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-24-099 |
| Funding Opportunity Title: | NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.855 — Allergy and Infectious Diseases Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jan 29, 2024 |
| Last Updated Date: | Jan 29, 2024 |
| Original Closing Date for Applications: | Jan 13, 2027 |
| Current Closing Date for Applications: | Jan 13, 2027 |
| Archive Date: | Feb 18, 2027 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Notice of Funding Opportunity (NOFO) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials related to the research mission of the NIAID. This program provides support for hypothesis-driven, milestone-driven clinical trials. Although clinical trials not considered high-risk may be proposed, this program encourages high-risk clinical studies. High- risk does not imply human subject or patient risk, but rather defines a study that contains one or more of the following unique features: involves non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged and may be proposed under this program. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-24-099.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 352061 Full Announcement-PAR-24-099 -> PAR-24-099-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or before January 24, 2025 | PKG00284619 | Apr 12, 2024 | Jan 24, 2025 | View | |
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00289247 | Nov 27, 2024 | Jan 13, 2027 | View |
Package 1
Mandatory forms
352061 RR_SF424_5_0-5.0.pdf
352061 PHS398_CoverPageSupplement_5_0-5.0.pdf
352061 RR_OtherProjectInfo_1_4-1.4.pdf
352061 PerformanceSite_4_0-4.0.pdf
352061 RR_KeyPersonExpanded_4_0-4.0.pdf
352061 RR_Budget_3_0-3.0.pdf
352061 PHS398_ResearchPlan_5_0-5.0.pdf
352061 SBIR_STTR_Information_3_0-3.0.pdf
352061 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
352061 RR_SubawardBudget30_3_0-3.0.pdf
352061 PHS_AssignmentRequestForm_4_0-4.0.pdf
Package 2
Mandatory forms
352061 RR_SF424_5_0-5.0.pdf
352061 PHS398_CoverPageSupplement_5_0-5.0.pdf
352061 RR_OtherProjectInfo_1_4-1.4.pdf
352061 PerformanceSite_4_0-4.0.pdf
352061 RR_KeyPersonExpanded_4_0-4.0.pdf
352061 RR_Budget_3_0-3.0.pdf
352061 PHS398_ResearchPlan_5_0-5.0.pdf
352061 SBIR_STTR_Information_3_0-3.0.pdf
352061 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
352061 RR_SubawardBudget30_3_0-3.0.pdf
352061 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
